

11. (twice amended). An isolated biologically active polypeptide selected from the group consisting of:

- a) the polypeptide of any of SEQ ID NOs: 4, 5, and 6;
- b) a fragment of any of SEQ ID NOs: 4, 5, and 6;
- c) a polypeptide having one to fifty conservative amino acid changes as compared with the polypeptide of SEQ ID NO:4; and
- d) the polypeptide encoded by the DNA vector insert of ATCC Deposit Nos. 207158 and 207159.

12. (thrice amended) An isolated biologically active polypeptide encoded by a nucleic acid molecule selected from the group consisting of:

- a) a nucleic acid molecule as set forth in any of SEQ ID Nos:1, 2, and 3;
- b) a nucleic acid molecule encoding the polypeptide of any of SEQ ID NOs: 4, 5, and 6;
- c) fragments of SEQ ID NOs: 1, 2, and 3;
- d) a nucleic acid molecule of the DNA vector insert in ATCC deposit No. 207158;
- e) a nucleic acid molecule of the DNA vector insert in ATCC deposit No. 207159; and
- f) a nucleic acid molecule having one to fifty conservative amino acid substitutions as compared with the polypeptide of SEQ ID NO:4.

#### REMARKS


Claims 11-14 and 18-20 are pending in the subject patent application, claims 10 and 17 having been cancelled in Applicants' Response mailed September 4, 2001.

Applicants thank Examiner Rao for the telephone conference call with Applicants' representative, Nancy Oleski, on November 26, 2001. During that call, Examiner Rao agreed that all pending claims were in condition for allowance if the reference to allelic variants and splice variants were removed from claims 11 and 12.

Accordingly, claims 11 and 12 have been amended herein without prejudice to delete the embodiments directed to allelic variants and splice variants. Applicants reserve the right to prosecute this subject matter in a related application. No new matter has been added by these amendments.

Applicants believe that the claims are now in condition for allowance, and a notice to that effect is respectfully solicited.

Respectfully submitted,



Nancy A. Oleski  
Attorney for Applicant(s)  
Registration No.: 34,688  
Phone: (805) 447-6504  
Date: December 7, 2001

Please send all future correspondence to:

U.S. Patent Operations/ NAO  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

VERSION WITH MARKINGS TO SHOW CHANGES MADE

11. (twice amended). An isolated biologically active polypeptide selected from the group consisting of:

- a) the polypeptide of any of SEQ ID NOs: 4, 5, and 6;
- b) a fragment of any of SEQ ID NOs: 4, 5, and 6;
- c) a polypeptide having one to fifty conservative amino acid changes as compared with the polypeptide of SEQ ID NO:4; and
- d) the polypeptide encoded by the DNA vector insert of ATCC Deposit Nos. 207158 and 207159; and
- e) a polypeptide that is an allelic variant or splice variant of (a).]

12. (thrice amended) An isolated biologically active polypeptide encoded by a nucleic acid molecule selected from the group consisting of:

- a) a nucleic acid molecule as set forth in any of SEQ ID Nos:1, 2, and 3;
- b) a nucleic acid molecule encoding the polypeptide of any of SEQ ID NOs: 4, 5, and 6;
- c) fragments of SEQ ID NOs: 1, 2, and 3;
- [d] an allelic variant or splice variant of any of (a) or (b);]
- [e)] d) a nucleic acid molecule of the DNA vector insert in ATCC deposit No. 207158;
- [f)] e) a nucleic acid molecule of the DNA vector insert in ATCC deposit No. 207159; and
- [g)] f) a nucleic acid molecule having one to fifty conservative amino acid substitutions as compared with the polypeptide of SEQ ID NO:4.